QuEST - Quick and Easy Scrub Typhus Diagnostic Tools
QuEST
Diagnostic Tools for the Direct Detection of Orientia Tsutsugamushi
1 other identifier
observational
345
1 country
3
Brief Summary
Evaluate the performance of insulated isothermal polymerase chain reaction (iiPCR) in the diagnosis of scrub typhus in Chiang Rai Province
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2024
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 17, 2024
CompletedFirst Submitted
Initial submission to the registry
November 4, 2024
CompletedFirst Posted
Study publicly available on registry
November 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2026
CompletedMay 1, 2026
April 1, 2026
1.5 years
November 4, 2024
April 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sensitivity, specificity, positive- and negative predictive values of insulated isothermal polymerase chain reaction (iiPCR) compared to reference diagnostic tests
Baseline and week two
Secondary Outcomes (2)
G6PD deficiency estimates
Week two
Risk exposure comparisons between healthy controls and scrub typhus cases
Baseline
Study Arms (1)
Suscpected scrub typhus cases
Participants with symptoms and epidemiologic risks for of scrub typhus and testing positive by: 1. StandardQ rapid diagnostic test OR 2. InBios Scrub Typhus Detect IgM 3. Insulated isothermal PCR
Eligibility Criteria
Febrile patients suspected of having scrub typhus and presenting to Mae Chan or Mae Suai district hospitals
You may qualify if:
- ≥ 7 years old AND
- Weight\>15Kg AND
- The patient and/or where relevant their parent/guardian/caretaker/LAR willing and able to give informed consent /assent for participation in the study AND
- Acute (duration ≤14 days) fever (37.5°C or higher or a history of fever in the previous 24h)
- For study group • Eschar OR Positivity to any of the screening tests (Immunochromatographic RDT or iiPCR)
- For negative control
- Negativity to all screening tests (ten patients per hospital)
You may not qualify if:
- Other clear focus of infection (e.g. lobar pneumonia by chest x-ray, abscess) OR
- Other clear cause of fever (e.g. positive Dengue IgM or NS1 antigen, positive blood cultures, untreated HIV)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Mae Chan District Hospital
Mae Chan, Changwat Chiang Rai, Thailand
Mae Fah Luang District Hospital
Chiang Rai, Thailand
Mae Suai District Hospital
Chiang Rai, Thailand
Biospecimen
Whole blood in EDTA and clotted blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Carlo Perrone, MD
Mahidol Oxford Tropical Medicine Research Unit
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 4, 2024
First Posted
November 5, 2024
Study Start
July 17, 2024
Primary Completion
January 31, 2026
Study Completion
February 28, 2026
Last Updated
May 1, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
After publication of main findings, or 1 year after study completion (whichever comes first) and reasonable request to MORU data access committee